» Articles » PMID: 21364020

STAT-3 Activates NF-kappaB in Chronic Lymphocytic Leukemia Cells

Overview
Journal Mol Cancer Res
Specialty Cell Biology
Date 2011 Mar 3
PMID 21364020
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

NF-κB plays a major role in the pathogenesis of B-cell neoplasms. A broad array of mostly extracellular stimuli has been reported to activate NF-κB, to various degrees, in chronic lymphocytic leukemia (CLL) cells. Because CLL cells harbor high levels of unphosphorylated STAT-3 (USTAT-3) and USTAT-3 was reported to activate NF-κB, we sought to determine whether USTAT-3 activates NF-κB in CLL. Using the electrophoretic mobility shift assay (EMSA), we studied peripheral blood low-density cells from 15 patients with CLL and found that CLL cell nuclear extracts from all the samples bound to an NF-κB DNA probe, suggesting that NF-κB is constitutively activated in CLL. Immunoprecipitation studies showed that STAT-3 bound NF-κB p65, and confocal microscopy studies detected USTAT-3/NF-κB complexes in the nuclei of CLL cells, thereby confirming these findings. Furthermore, infection of CLL cells with retroviral STAT-3-short hairpin RNA attenuated the binding of NF-κB to DNA, as assessed by EMSA, and downregulated mRNA levels of NF-κB-regulated genes, as assessed by quantitative PCR. Taken together, our data suggest that USTAT-3 binds to the NF-κB p50/p65 dimers and that the USTAT-3/NF-κB complexes bind to DNA and activate NF-κB-regulated genes in CLL cells.

Citing Articles

Targeting STAT3 for Cancer Therapy: Focusing on Y705, S727, or Dual Inhibition?.

Berkley K, Zalejski J, Sharma A Cancers (Basel). 2025; 17(5).

PMID: 40075607 PMC: 11898704. DOI: 10.3390/cancers17050755.


Tumor Cell Survival Factors and Angiogenesis in Chronic Lymphocytic Leukemia: How Hot Is the Link?.

Ayoub M, Susin S, Bauvois B Cancers (Basel). 2025; 17(1.

PMID: 39796700 PMC: 11719013. DOI: 10.3390/cancers17010072.


Action Mechanism of Metformin and Its Application in Hematological Malignancy Treatments: A Review.

Zhang Y, Zhou F, Guan J, Zhou L, Chen B Biomolecules. 2023; 13(2).

PMID: 36830619 PMC: 9953052. DOI: 10.3390/biom13020250.


The Pt(-pr-thiosal)2 and BCL1 Leukemia Lymphoma: Antitumor Activity In Vitro and In Vivo.

Silconi Z, Rosic V, Benazic S, Radosavljevic G, Mijajlovic M, Pantic J Int J Mol Sci. 2022; 23(15).

PMID: 35897737 PMC: 9332548. DOI: 10.3390/ijms23158161.


Regulation of S100As Expression by Inflammatory Cytokines in Chronic Lymphocytic Leukemia.

Ajtic O, Suboticki T, Diklic M, dikic D, Vukotic M, Dragojevic T Int J Mol Sci. 2022; 23(13).

PMID: 35805957 PMC: 9267105. DOI: 10.3390/ijms23136952.


References
1.
Romano M, Lamberti A, Tassone P, Alfinito F, Costantini S, Chiurazzi F . Triggering of CD40 antigen inhibits fludarabine-induced apoptosis in B chronic lymphocytic leukemia cells. Blood. 1998; 92(3):990-5. View

2.
Nishio M, Endo T, Tsukada N, Ohata J, Kitada S, Reed J . Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1alpha. Blood. 2005; 106(3):1012-20. PMC: 1895149. DOI: 10.1182/blood-2004-03-0889. View

3.
Bourillot P, Aksoy I, Schreiber V, Wianny F, Schulz H, Hummel O . Novel STAT3 target genes exert distinct roles in the inhibition of mesoderm and endoderm differentiation in cooperation with Nanog. Stem Cells. 2009; 27(8):1760-71. DOI: 10.1002/stem.110. View

4.
Endo T, Nishio M, Enzler T, Cottam H, Fukuda T, James D . BAFF and APRIL support chronic lymphocytic leukemia B-cell survival through activation of the canonical NF-kappaB pathway. Blood. 2006; 109(2):703-10. PMC: 1890820. DOI: 10.1182/blood-2006-06-027755. View

5.
Munzert G, Kirchner D, Stobbe H, Bergmann L, Schmid R, Dohner H . Tumor necrosis factor receptor-associated factor 1 gene overexpression in B-cell chronic lymphocytic leukemia: analysis of NF-kappa B/Rel-regulated inhibitors of apoptosis. Blood. 2002; 100(10):3749-56. DOI: 10.1182/blood.V100.10.3749. View